L'Oréal, the global cosmetics group, has said that the rising use of a class of weight‑loss medicines is influencing demand across its beauty and skin care businesses. The company’s chief executive described the trend as “a very important phenomenon for us.”
The medicines in question belong to the glucagon‑like peptide‑1 (GLP‑1) class, which have been increasingly used for weight management in a number of markets. Their growing popularity has drawn attention across consumer sectors as firms assess how changing body‑shaping and health habits might alter shopping patterns.
L'Oréal told investors and observers that the uptake of GLP‑1s has had a measurable effect on sales in some product categories within its portfolio. The company said the trend is significant enough to warrant close attention from senior management as they monitor consumer behaviour.
Industry watchers say developments in health and wellness can reverberate through cosmetics and personal care markets because they influence how consumers prioritise and use beauty products. L'Oréal's comments underline how broader shifts in medical treatments or lifestyles can become relevant to companies outside the healthcare sector.
The group's remarks add to a wider conversation among beauty manufacturers about how to respond to changing demand drivers. Executives and investors will be watching whether the trend persists and how it may shape product development and marketing strategies going forward.